Regimen | Patient population | N | Median age [range], years | Induction mortality, % | CR/CRi rate, % | MRD negativity, % | HSCT rate, % | CR duration, % | OS rate, % | Reference |
---|---|---|---|---|---|---|---|---|---|---|
R/R Ph-negative ALL | ||||||||||
Mini-HCVD + InO ± blinatumomab | Primary refractory 13% CR1 duration < 1 year 40% Prior HSCT 23% | 84 | 35 [9-87] | 2 | 80 | 80 | 40 | 52% (2-year) | 39 (2-year) | [28] |
CVP + InO (SWOG 1312) | Salvage 1: 44% Prior blinatumomab 38% Prior HSCT 19% | 48 | 43 [20-79] | 2 | 61 | NR | 30 | NR | Median 10.9 months | [29] |
Venetoclax + navitoclax | B cell ALL 50% T cell ALL 50% Median prior therapies: 4 Prior HSCT 14% Prior CAR T cells 17% | 36 | 29 [6-72] | 8 | 56 | 56 | 25 | 44% (6-month) | NR | [30] |
Frontline Ph-negative older ALL | ||||||||||
Mini-HCVD + InO ± blinatumomab | Age ≥ 60 years | 64 | 68 [60-81] | 0 | 98 | 95 | 5 | 76% (3-year) | 54 (3-year) | [31] |
Blinatumomab + POMP (SWOG 1318) | Age > 60 years | 31 | 73 [66-84] | 0 | 66 | 92 | 3 | DFS 56 (1-year) | 65 (1-year) | [32] |
Frontline Ph-negative younger ALL | ||||||||||
Sequential HCVAD + blinatumomab | Age < 60 years | 27 | 38 [18-59] | 0 | 100 | 96 | 30 | RFS 76 (1-year) | 89 (1-year) | [33] |